These results also suggest that the mechanism of ESF catabolism by the liver is similar to that reported for certain other plasma glycoproteins. ESF from the circulation of the assay animals before it can exert its effects upon target cells in the marrow (6, 11). However, it has not been demonstrated that desialylated ESF is removed from the circulation more rapidly than is the intact glycoprotein.
Also, the role of the liver in this process has not been well defined.
The present studies were conducted to investigate the clearance of intact and desialylated ESF by the liver and to evaluate the effects of competitive inhibitors on this m-ocess,
MATERIALS AKD METHODS
Both an in vivo and an in vitro assay for erythropoietin were employed in these studies. The in vivo exhypoxic polycythemic mouse assay (2,. 4), which measures 5 gFe incorporation in RBC, can detect intact erythropoietin but not erythropoietin desialylated (dES$) with neuraminidase (10, 18). The in vitro rabbit bone marrow culture (8, 9), which determines sgFe incorporation into heme, can detect both ESF and dESF (5). For this assay, the femoral bone marrow was removed from male New Zealand albino rabbits and suspended in 20 % new-born calf serum and 80 % NCTC-109 medium. Each marrow culture plate contained 2 X 106 viable nucleated cells in 2 ml, The culture plates were stimulated with 20 ~1 of a test sample or a standard preparation of human urinary ESF and were incubated att 37°C in 95 % air, 5 % COZ, and 95 % humidity.
After 29 h, 0.5 &i of 59Fe was added to each plate and the incubation was continued for an additional 16 h. The cells were lysed with Drabkin's solution and the acidified heme was extracted with cyclohexanone.
Serum from hypoxic rats (HRS) was employed as the source of ing male ESF in these studies. HRS was obtained by exposSprague-Dawley rats to 0.42 atm pressure for I8 h in a hypobaric chamber. Upon removal from the chamber the rats were immediately anesthetized with ether and exsanguinated via the abdominal aorta. HRS was obtained from the blood of several rats, pooled, and assayed for ESF in the pdycythemic mouse assay. One milliliter of HRS was found to contain approximately 1 U of ESF. Desialylation of ESF was accomplished by incubating 15 ml HRS with 67.5 U of Vibrio cholera neuraminidase (General Biochemicals) at 37°C for 2 h in a Dubnoff metabolic shaker, Aliquots of several concentrations of intact HRS or desialylated HRS were assayed for erythropoietic activity in both the in vivo polycythemic mouse assay and the in vitro marrow assay in order to determine whether the incubation of HRS with neuraminidase was desialylating ESF and thereby inactivating it in the in vivo assay system* Neuraminidase was also tested alone at several concentrations in both assay systems in order to determine any direct effects that this enzyme itself might have on jgFe incorporation into newly formed red cells. Orosomucoid (ORM) was obtained from human plasma by the method of Weimer et al, (20) and was desialylated by incubating 50 mg of the freeze-dried glycoprotein for 24 h at 37°C with 150 U neuraminidase in a total volume of 1.3 ml (12).
The hepatic perfusion medium employed in these experiments was a modification of that described by Brauer et al. (1). Bovine serum albumin 2.3 g, 37.5 mg NaHC03, 460 mg NaCl, 21 mg KCl, and 6 mg CaCls in a total volume of 50 ml distilled water was combined with 5 ml of 0.1 M phosphate buffer (pH 7.4). Thirty milliliters of heparinized whole-rat blood were then added and the total mixture was equilibrated at 37°C with a humidified gas mixture (95 % 02,5 % COZ) in an organ perfusion apparatus.
The medium was maintained at pH 7.4 by addition of 8 % NaHC03 solution, as required, throughout the perfusion period. Livers for perfusion were obtained from male SpragueDawley rats (225 g) anesthetized with ether. The abdominal cavity was opened and the bile duct was cannulated with PIE-10 tubing. The portal vein was cannulated with PIE-100 tubing and the liver was immediately flushed with l-2 ml heparinized saline. The liver with diaphragm attached was then quickly excised and placed in the perfusion apparatus. Hepatic perfusion via the portal vein was begun immediately at a pressure of 20-22 cmHz0.
This resulted in a flow rate through the liver of 1 O-1 2 ml/min.
Each liver was allowed to equilibrate for 10-l 5 min until oxygen consumption and bile production were evident. Following an initial sampling of the perfusate for use as a control, 15 ml of HRS or dHRS containing 15 U ESF (or dESF) were added to the perfusion medium.
This addition occurred over a 3-min period, and an additional 5 min was allowed to ensure equilibration of the ESF throughout the perfusion medium. During certain experiments, ORM or desialylated ORM (dORM) was also added to the perfusate, either at the time of the addition of dHRS or 1 h later. Perfusate samples were taken at various times following the addition of ESF to the perfusion medium. These samples were centrifuged (2,000 X g, 10 min) and the supernatants decanted and frozen until assayed for ESF or dESF in the in vitro rabbit bone marrow assay.
Liver viability was assessed by monitoring 02 consumption and bile production throughout the perfusion period (15). Oxygen consumption was calculated from hepatic blood Aow, hemoglobin content of the perfusate, and the BRIGGS, FISHER, AND GEORGE arterial-venous oxygen differences, which were determined with a blood-gas analyzer (Instrumentation Laboratory, Inc., model 113). Arterial and venous Pcoz levels, pH, and hematocrit were also monitored. Following perfusion, the livers were sectioned and compared histologically to nonperfused livers for evidence of sinusoidal congestion or cellular degenera tion.
RESULTS

A comparison
of the in vivo and in vitro assay systems for erythropoietin indicates that HRS had significant activity in both assays. Although dHRS was without significant erythropoietic activity in the polycythemic mouse assay, its activity was equal to or greater than that of HRS when assayed in the marrow culture (Fig. 1) . Neuraminidase alone had no significant effect on 5gFe incorporation in either assay system. Control experiments were conducted in which HRS or dHRS was added to the perfusion medium and circulated for 6 h through the perfusion system with no liver present. The erythropoietic activity of these perfusates remained constant throughout the 6 h of perfusion. There was no significant difference in erythropoietic activity between perfusates containing HRS and those containing dHRS. Figure 2 depicts two representative experiments in which livers were perfused with either HRS, dHRS, or with normal rat serum (NRS) f rom animals not exposed to hypoxia. At various time intervals, perfusate samples were removed from the system and assayed for erythropoietic activity in the marrow culture. The perfusate containing NRS did not possess significant erythropoietic activity at any time (cxperimerit I). However, the perfusates containing intact HRS exhibited significant increases in erythropoietic activity as early as 5 min following HRS addition and retained this activity for at least 4 h (experiments 1 and 11). The activity of the perfusates containing dHRS also was significantly increased at the 5-min period, but this activity declined significantly after only 15 min of perfusion and continued to decrease during the remainder of the perfusion period. Addition of a single 50-mg dose of dORM to the perfusion medium at the same time as the dHRS addition main- fates other glycoproteins besides ESF, it is not possible to exclude a role for other desialylated glycoproteins in the enhanced erythropoietic activity of dHRS seen with the tained, for at least 1 h, a level of erythropoietic activity which was significantly greater than that observed after addition of dHRS alone (Fig. 3) . After 2 h of perfusion, the activity of the perfusate containing dORM plus dHRS had declined to a level equal to that of the perfusate containing dHRS alone.
In an additional series of experiments, a second 50-mg dose of dORM was added to the perfusion medium after 1 h of perfusion. When this additional dose was given, the activity of the dHRS-dORM perfusate remained elevated throughout the entire perfusion period (Fig. 4) . When two doses of "intact" ORM were substituted for dORM, the perfusate did not maintain elevated levels of erythropoietic activity, but instead the activity declined in a manner similar to that observed with dHRS alone (Fig. 4) .
A series of experiments was also conducted in order to determine whether ORM or dORM was directly enhancing the stimulatory effect of HRS or dHRS on 5gFe incorporamarrow culture assay. Goldwasser et al. (6) reported a threefold increase in the activity of dESF over intact ESF when these substances were compared in dilute concentrations in the marrow assay. Our results do not support this finding, since after dilution in the perfusion medium, HRS and dHRS exhibited comparable erythropoietic potency in the marrow cultures. However, both our source of ESF and our assay methods differed from those employed by these investigators and this may explain the difference in the results. As shown in Figs. 2-4 , the initial activities of the perfusates containing dHRS alone were usually lower than the initial activities of intact HRS or of dHRS plus dORM. Since the initial samples were taken after 5 min of perfusion, hepatic clearance of the dESF added to the medium may have already begun, thus resulting in the lower erythropoietic activity.
Our results are in agreement with the proposal that ESF may be rapidly cleared by the liver following desialylation (6). Intact ESF appears to be removed at a much slower BRXGGS, FISHER, AND GEORGE rate than the desialylated substance (Fig. 2) . Since neuraminidase exists in normal mammalian plasma (X9), it is possible that desialylation may be an early step in the clearance of ESF and other glycoproteins from the circulation. Our data do not provide direct evidence that dESF enters the interior cf the hepatic cells. However, since a single dose of dORM could sustain the erythropoietic activity of the perfusate only temporarily (Fig. 3) , it is probably that dORM was being preferentially cleared by the liver and thereby competitively inhibiting the uptake of dESF. Once dORM was removed from the perfusate, dESF could be rapidly cleared, resulting in the observed decline in erythropoietic activity to control levels. The results of repeated administration of d0RM (Fig* 4) , together with the studies of Morel1 et al. (12) 
